{"slug":"issue-98","tag":"issue-98","variants":["issue-98"],"description":"No description yet","count":1,"kinds":{"trial":1},"related":[{"slug":"pipeline","tag":"pipeline","shared":1}],"records":[{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","status":"positive","tldr":"In LITESPARK-011, belzutifan plus lenvatinib held advanced clear-cell kidney cancer in check for about four months longer than cabozantinib in people whose cancer had grown after immunotherapy, but at the interim look it had not been shown to help them live longer; a final survival analysis is still to come."}]}